First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Clinical trial NCT05489237 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05489237
Sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Gastrointestinal Neoplasms Gastrointestinal Stromal Tumor (GIST)Digestive System Disease Gastrointestinal Diseases Metastatic Cancer

Start date: 2022-08-03
Primary completion: 2027-03-10
Enrollment: 276

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.